Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sorin Hopes Improving CRT Response Rate Will Lead To Growth In U.S. Market

This article was originally published in The Gray Sheet

Executive Summary

The Italian company is set to launch the RESPOND CRT trial of its SonR cardiac resynchronization therapy, which Sorin expects will be an important differentiator that allows the company to compete more aggressively in the U.S. market.


Related Content

Research In Brief
More Patients Should Receive Cardiac Resynchronization Therapy, Heart Groups Say


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts